Clinical trial
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
NCT00059787 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00059787 |
|---|---|
| Title | Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma |
| Official title | Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer |
| Intervention type | Drug |
| Interventions | paclitaxel, carboplatin, erlotinib |
| Enrollment | 56 |
| Start date | Apr 1, 2003 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | May 7, 2003 |
| Last update posted | Dec 1, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: